食管癌根治性放化疗后挽救性内镜切除术:西方经验
欧洲和美国10个内镜中心的胃肠病学家提交了25例食管癌患者根治性放化疗后行挽救性内镜黏膜下剥离术或内镜黏膜切除术的数据,共35次操作,整块切除率ESD为92%、EMR为46%,随访中位24个月52%复发,5年无复发生存率36%、总生存率52%、疾病特异性生存率79%,无重大不良事件。
要点
- 在精心选择的食管癌患者中,根治性放化疗后行挽救性内镜切除术技术上可行。
- 共35次挽救性内镜切除术,69%为内镜黏膜下剥离术,31%为内镜黏膜切除术。
- 整块切除率ESD为92%,EMR为46%;未报告出血或穿孔等重大术中或术后不良事件。
核心结论
- 在精心选择的食管癌患者中,根治性放化疗后行挽救性内镜切除术技术上可行。
- 建议进一步开展前瞻性研究以验证挽救性内镜切除术治疗局部失败的安全性和有效性。
研究设计与样本
- 邀请欧洲和美国的胃肠病学家提交根治性放化疗后行挽救性内镜黏膜下剥离术或内镜黏膜切除术的经验。
- 参与胃肠病学家填写匿名数据库,包括患者人口学、临床病理变量以及生存和复发随访。
- 来自6个欧洲国家10个内镜单位的胃肠病学家提交了25例患者的信息。
- 共实施35次挽救性内镜切除术,其中69%为内镜黏膜下剥离术,31%为内镜黏膜切除术。
主要发现
- 多数患者为鳞状细胞癌(64%),位于食管中段或下段(68%),根治性放化疗前分期为cT2-3(68%)和cN+(52%)。
- 从根治性放化疗结束到内镜切除术的中位时间为22个月(四分位距6-47)。
- 整块切除率内镜黏膜下剥离术为92%,内镜黏膜切除术为46%。
- 挽救性内镜切除术后中位随访24个月(四分位距12-59),52%出现复发(11例局部区域,2例远处)。
- 5年无复发生存率、总生存率和疾病特异性生存率分别为36%、52%和79%。
临床怎么用
- 在精心选择的食管癌患者中,根治性放化疗后行挽救性内镜切除术技术上可行。
- 作者建议进一步开展前瞻性研究以验证挽救性内镜切除术治疗局部失败的安全性和有效性。
局限性
- 建议进一步开展前瞻性研究以验证挽救性内镜切除术治疗局部失败的安全性和有效性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Definitive chemoradiotherapy (CRT) is increasingly used as a nonsurgical treatment for esophageal cancer. In Japanese studies, salvage endoscopic resection (ER) has emerged as a promising strategy for local failure after definitive CRT. We aimed to evaluate the safety and efficacy of salvage ER in a Western setting. METHODS: Gastroenterologists from Europe and the United States were invited to submit their experience with salvage endoscopic submucosal dissection (ESD) or endoscopic mucosal resection (EMR) after definitive CRT. Participating gastroenterologists completed an anonymized database, including patient demographics, clinicopathologic variables, and follow-up on survival and recurrence. RESULTS: Gastroenterologists from 10 endoscopic units in 6 European countries submitted information on 25 patients. A total of 35 salvage ER procedures were performed, of which 69% were ESD and 31% EMR. Most patients had squamous cell carcinoma (64%) of the middle or lower esophagus (68%) staged as cT2-3 (68%) and cN+ (52%) before definitive CRT. The median time from end of definitive CRT to ER was 22 months (interquartile range, 6-47). The en-bloc resection rate was 92% for ESD and 46% for EMR. During a median of 24 months (interquartile range, 12-59) of follow-up after salvage ER, 52% developed a recurrence (11 locoregional, 2 distant). The 5-year recurrence-free survival, overall survival, and disease-specific survival were 36%, 52%, and 79%, respectively. No major intra- or postprocedural adverse events, such as bleeding or perforation, were reported. CONCLUSIONS: In carefully selected esophageal cancer patients, salvage ER is technically feasible after definitive CRT. Further prospective research is recommended to validate the safety and effectivity of salvage ER for the management of local failure.
引用
- Al-Kaabi A, Schoon EJ, Deprez PH, et al. Salvage endoscopic resection after definitive chemoradiotherapy for esophageal cancer: a Western experience. Gastrointest Endosc. 2020. PMID: 32763242. doi:10.1016/j.gie.2020.07.062
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。